Neil A. Klompas is CFO at Zymeworks Inc. (ZYME). They have made 3 open-market trades across 1 company since 2019, most recently 2023-03-10.
CIK 0001761857
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ZYME | 17,032 | $426K |
Shares reported on the most recent Form 4, priced at the 2023-03-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZYME | SELL | 2023-03-10 | 2023-03-14 | $7.83 | $23K | -2.3% | +20.0% | -0.4% |
| ZYME | SELL · 10b5-1 | 2022-03-10 | 2022-03-11 | $6.88 | $20K | +7.4% | -10.1% | -5.5% |
| ZYME | SELL · 10b5-1 | 2021-03-10 | 2021-03-12 | $34.95 | $50K | -10.4% | -19.6% | +6.2% |
| ZYME | SELL | 2020-12-09 | 2020-12-11 | $53.25 | $1.3M | -1.7% | +8.4% | -30.0% |
| ZYME | SELL | 2019-05-06 | 2019-05-08 | $19.22 | $289K | -0.2% | +13.3% | +26.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.